Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 9:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–45 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neuroprotective Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phenytoin as a Neuroprotective Agent Against Corticosteroid-induced Functional Imaging Changes

NCT00591006
View directory record Official record
Conditions
Healthy
Interventions
Phenytoin (brand name Dilantin), Hydrocortisone, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Sep 12, 2026, 9:55 AM EDT
Active, not recruiting Phase 2 Interventional

Minocycline for Aneurysmal Subarachnoid Hemorrhage (MASH)

NCT04876638
View directory record Official record
Conditions
Aneurysm, Ruptured, Vasospasm, Intracranial, Delayed Cerebral Ischemia, Blood Brain Barrier Defect
Interventions
Minocyclin
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Sep 12, 2026, 9:55 AM EDT
Active, not recruiting Not applicable Interventional

Functional and Neuroprotective Effects of Restoring Lower Limb Sensation After Diabetic Peripheral Neuropathy

NCT04658693
View directory record Official record
Conditions
Lower Extremity Amputee, Diabetic Peripheral Neuropathy
Interventions
Implanted Multi contact stimulating electrode and intramuscular electromyography recording electrode
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 12, 2026, 9:55 AM EDT
Active, not recruiting Not applicable Interventional

Partnered Dance Aerobic Exercise as a Neuroprotective, Motor and Cognitive Intervention in Parkinson's Disease

NCT04122690
View directory record Official record
Conditions
Parkinson's Disease, Exercise Therapy, Cognition
Interventions
PDAE, WAE
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 89 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 12, 2026, 9:55 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)

NCT01188811
View directory record Official record
Conditions
Multiple Sclerosis, Chronic Progressive
Interventions
lipoic acid, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Sep 12, 2026, 9:55 AM EDT
Withdrawn Phase 2 Interventional

Safety and Brain Protection Effects of the Green Tea Extract Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis

NCT02011451
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
95% Pure ECGC capsules 200mg, Placebo Comparator:
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 25, 2016 · Synced Sep 12, 2026, 9:55 AM EDT
Completed Not applicable Interventional

Treatment of Refractory Schizophrenia With Riluzole

NCT00375050
View directory record Official record
Conditions
Schizophrenia, Schizoaffective
Interventions
Riluzole, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Sep 12, 2026, 9:55 AM EDT
Completed Phase 1 Interventional

Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS

NCT03520517
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS, Lou Gehrig Disease, Lou Gehrig's Disease, Lou-Gehrigs Disease, Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Interventions
BHV-0223
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Lincoln, Nebraska • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Sep 12, 2026, 9:55 AM EDT
Active, not recruiting Phase 2 Interventional

Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis

NCT05122559
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Interventions
N-acetyl cysteine, Placebo
Drug
Lead sponsor
Emmanuelle Waubant, MD PhD
Other
Eligibility
40 Years to 70 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 12, 2026, 9:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Clinical Trial of Pramipexole in Bipolar Depression

NCT00025792
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Pramipexole
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 12, 2026, 9:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Caffeinol Hypothermia Protocol

NCT00299416
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Caffeinol, hypothermia
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 2, 2011 · Synced Sep 12, 2026, 9:55 AM EDT
Withdrawn Phase 1 Interventional

Intra-Arterial Neuroprotective Agents and Cold Saline in Ischemic Stroke Intervention

NCT05032781
View directory record Official record
Conditions
Stroke, Ischemic
Interventions
Intra-arterial cold saline, minocycline, and magnesium
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 12, 2026, 9:55 AM EDT
Recruiting Early Phase 1 Interventional

Melatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia

NCT02621944
View directory record Official record
Conditions
Hypoxic Ischemic Encephalopathy
Interventions
Melatonin, Magnetic Resonance Imaging, Pharmacokinetics, Neurological Outcome Assessment
Drug · Other · Behavioral
Lead sponsor
University of Florida
Other
Eligibility
Up to 6 Hours
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
2
States / cities
Gainesville, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 12, 2026, 9:55 AM EDT
Completed Phase 3 Interventional Results available

Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants

NCT03169881
View directory record Official record
Conditions
Neurocognitive, Neuroprotective, Neonatal, Neurodevelopmental Impairment
Interventions
Darbepoetin, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
1 Hour to 24 Hours
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
16
States / cities
Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 12, 2026, 9:55 AM EDT
Completed Phase 2 Interventional Results available

Parkinson's Disease Isradipine Safety Study

NCT00753636
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Dynacirc CR (Isradipine)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
30 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 14, 2021 · Synced Sep 12, 2026, 9:55 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II

NCT01451723
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Polyphenon E, Placebo
Drug · Other
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Sep 12, 2026, 9:55 AM EDT
Terminated Not applicable Interventional Results available

Treatment of Subarachnoid Hemorrhage With Human Albumin

NCT00283400
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
25% human albumin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 79 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
4
States / cities
Baltimore, Maryland • Hershey, Pennsylvania • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Sep 12, 2026, 9:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Is Cognitive Training Neuroprotective in Early Psychosis?

NCT03049800
View directory record Official record
Conditions
Psychosis, Healthy
Interventions
Magnetic Resonance Imaging
Device
Lead sponsor
University of Minnesota
Other
Eligibility
16 Years to 35 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Sep 12, 2026, 9:55 AM EDT
Completed Not applicable Interventional

Effect of Osteopathic Manipulative Medicine on Parkinson Disease

NCT02107638
View directory record Official record
Conditions
Parkinson Disease
Interventions
OMM treatment arm, Counseling
Procedure · Other
Lead sponsor
New York Institute of Technology
Other
Eligibility
40 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Old Westbury, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Sep 12, 2026, 9:55 AM EDT
Completed Not applicable Interventional

The ParkCycle Study: Aerobic Exercise in PD

NCT01562496
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Exercise
Behavioral
Lead sponsor
Radboud University Medical Center
Other
Eligibility
30 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 12, 2014 · Synced Sep 12, 2026, 9:55 AM EDT
Completed Phase 2 Interventional

GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)

NCT01854294
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
GM604, Placebo comparator
Drug
Lead sponsor
Genervon Biopharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Sep 12, 2026, 9:55 AM EDT